Autres langues Cogent Biosciences, Inc.

Actions

COGT

US19240Q2012

Temps réel estimé Cboe BZX Autres places de cotation 21:14:08 07/05/2024			Varia. 5j.	Varia. 1 janv.
7,705 ^USD	+1,78%		+18,31%	+30,78%

19:25	Cogent Biosciences aggrave sa perte au 1er trimestre	MT
14:26	Cogent Biosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Cogent Biosciences Q1 Loss Widens	19:25
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14:26
Cogent Biosciences Reports First Quarter 2024 Financial Results	14:02
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)	18/04
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor	09/04
North American Morning Briefing : Stock Futures -2-	27/02
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	26/02
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	22/02
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	22/02
Top Midday Gainers	14/02
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump	14/02
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement	14/02
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting	05/02
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024	09/01
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics	09/01
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference	02/01
North American Morning Briefing : Traders Eye -2-	12/12
Sector Update: Health Care Stocks Higher Late Afternoon	11/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Cogent Biosciences, Inc.

Actions

COGT

US19240Q2012

Autres langues

Filtres